Preparation and evaluation of fenbendazole methyl-β-cyclodextrin inclusion complexes (2024)

Peer-Reviewed Study · Ding Y, Zhang Z, Ding C, Xu S, Xu Z · May 20, 2024

Ding Y et al., 2024-05-20: A formulation paper on fenbendazole solubility states in its introduction that fenbendazole shows anti-cancer effects in paclitaxel- and doxorubicin-resistant cancer cells, which is resistance reversal rather than a trial against doxorubicin.

As an orally effective benzimidazole anthelmintic agent, fenbendazole was not only widely used in agriculture and animal husbandry to prevent and treat parasites, but also shows anti-cancer effects against several types of cancer, exhibits anti-cancer effects in paclitaxel and doxorubicin-resistant cancer cells.

Ding Y et al., 2024-05-20: A formulation paper on fenbendazole solubility states in its introduction that fenbendazole shows anti-cancer effects in paclitaxel- and doxorubicin-resistant cancer cells, which is resistance reversal rather than a trial against doxorubicin. C3 breast/'beat doxorubicin'. Study type: pharmaceutical formulation plus in vitro release and in vivo pharmacokinetics (animals); country China; funder not listed in the abstract; conflicts: 'The authors declare no competing interests'; maker not stated; comparator N/A. This is the closest published statement to the book's 'fenbendazole beat doxorubicin' line: it asserts activity in doxorubicin-RESISTANT cells, not superiority to doxorubicin in patients. No head-to-head clinical or animal comparison of fenbendazole versus doxorubicin was found (esearch 'fenbendazole doxorubicin' returns this paper only). Study type: lab.